和黄医药(00013.HK)就FRUZAQLA将收一项里程碑付款

阿斯达克财经
22 Nov 2024

和黄医药(00013.HK) 公布,继FRUZAQLA 1毫克/5毫克胶囊在日本取得定价批准并由其合作伙伴武田(TAK.US)  推出商业上市用于治疗经治的转移性结直肠癌患者后,药物将收到一项里程碑付款。早前,FRUZAQLA已取得日本厚生劳动省(MHLW)的生产及销售批准。

该药物是日本超过十年来首个获批用于治疗转移性结直肠癌的口服创新靶向疗法,已获批用于治疗无法彻底治愈及无法切除,且化疗后病情进展的晚期或复发性结直肠癌。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-21 16:25。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10